RecruitingPhase 1NCT05683184
OMAR Opioid Use Disorder
Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder
Sponsor
Yale University
Enrollment
30 participants
Start Date
Mar 10, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Able to provide informed consent
- Male and female 18 years and older
- DSM-5 diagnosis of opioid use disorder (for OUD group)
- Physically healthy i.e., no clinically unstable medical conditions
- Written informed consent and have capacity to consent and comply with study procedures
Exclusion Criteria4
- Current neuro-psychiatric illness or severe systemic disease (opioid use disorder is permitted in the OUD group).
- Presence of ferromagnetic metal in the body or heart pacemaker
- Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits
- Are claustrophobic
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUG[11C]OMAR
For each \[11C\]OMAR PET scan, up to 20 mCi of \[11C\]OMAR will be administered.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05683184
Related Trials
GLP-1R Agonist Treatment for Opioid Use Disorder
NCT065484904 locations
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
NCT060677371 location
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
NCT066511779 locations
Adversity, Brain and Opioid Use Study
NCT063557781 location
Identifying Biomarkers Related to Opioid Use and Pain Response Following Traumatic Injury and Surgery
NCT076932701 location